Published in Ethiop Med J on October 01, 1974
Determination of the cytokine profile in American cutaneous leishmaniasis using the polymerase chain reaction. Clin Exp Immunol (1993) 1.88
Mechanisms associated with immunoregulation in human American cutaneous leishmaniasis. Clin Exp Immunol (1984) 1.40
In situ characterization of the cellular immune response in American cutaneous leishmaniasis. Clin Exp Immunol (1985) 1.13
Differing antibody IgG isotypes in the polar forms of leprosy and cutaneous leishmaniasis characterized by antigen-specific T cell anergy. Clin Exp Immunol (1995) 0.90
Differing lymphokine profiles of functional subsets of human CD4 and CD8 T cell clones. Science (1991) 6.12
Lymphocyte suppression in leprosy induced by unique M. leprae glycolipid. Nature (1984) 2.63
Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J Exp Med (1995) 2.30
A major T cell antigen of Mycobacterium leprae is a 10-kD heat-shock cognate protein. J Exp Med (1992) 1.93
Determination of the cytokine profile in American cutaneous leishmaniasis using the polymerase chain reaction. Clin Exp Immunol (1993) 1.88
Preliminary taxonomic studies on the leprosy bacillus. Br J Exp Pathol (1975) 1.83
Diffuse cutaneous leishmaniasis: a disease due to an immunological defect of the host. Trans R Soc Trop Med Hyg (1972) 1.69
Learning from lesions: patterns of tissue inflammation in leprosy. Proc Natl Acad Sci U S A (1988) 1.62
Elimination of Mycobacterium leprae subsequent to local in vivo activation of macrophages in lepromatous leprosy by other mycobacteria. Clin Exp Immunol (1974) 1.54
Detection of antibodies toward secreted mycobacterial antigen 85 in untreated leprosy patients' sera. Int J Lepr Other Mycobact Dis (1999) 1.41
Immunotherapy with a mixture of Mycobacterium leprae and BCG in different forms of leprosy and in Mitsuda-negative contacts. Int J Lepr Other Mycobact Dis (1982) 1.41
Activated suppressor T cells in leprosy. J Immunol (1982) 1.37
A test for the determination of competency in clearing bacilli in leprosy patients. Bull World Health Organ (1972) 1.34
Identification of the noncultivable pathogenic mycobacteria M. leprae and M. lepraemurium. Int J Lepr Other Mycobact Dis (1968) 1.33
Physicochemical characteristics of the glycosaminoglycan-lysosomal enzyme interaction in vitro. A model of control of leucocytic lysosomal activity. Biochem J (1976) 1.33
Characterization of Mycobacterium leprae cell wall-associated proteins with the use of T lymphocyte clones. J Immunol (1989) 1.29
HLA-linked control of predisposition to lepromatous leprosy. J Infect Dis (1985) 1.28
Immunological changes observed in indeterminate and lepromatous leprosy patients and Mitsuda-negative contacts after the inoculation of a mixture of Mycobacterium leprae and BCG. Clin Exp Immunol (1979) 1.26
ELECTRON MICROSCOPE STUDY OF MYCOBACTERIUM LEPRAE AND ITS ENVIRONMENT IN A VESICULAR LEPROUS LESION. J Bacteriol (1962) 1.25
Diagnosis of cutaneous leishmaniasis and species discrimination of parasites by PCR and hybridization. J Clin Microbiol (1994) 1.24
Immunotherapy versus chemotherapy in localised cutaneous leishmaniasis. Lancet (1987) 1.24
Studies on human polymorphonuclear leukocyte enzymes. I. Assay of acid hydrolases and other enzymes. Biochim Biophys Acta (1973) 1.21
Serum levels of tumor necrosis factor in patients with American cutaneous leishmaniasis. Biol Res (1993) 1.20
T-cell subpopulations, expression of interleukin-2 receptor, and production of interleukin-2 and gamma interferon in human American cutaneous leishmaniasis. J Clin Microbiol (1988) 1.17
Mycolic acids from "noncultivable" mycobacteria. Infect Immun (1974) 1.17
Immunological significance of Mycobacterium leprae cell walls. Proc Natl Acad Sci U S A (1988) 1.15
Lymphocyte transformation with phytomitogens in leprosy. Int J Lepr Other Mycobact Dis (1972) 1.15
Inhibition of leucocytic lysosomal enzymes by glycosaminoglycans in vitro. Biochem J (1975) 1.15
In situ characterization of the cellular immune response in American cutaneous leishmaniasis. Clin Exp Immunol (1985) 1.13
Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses. Br J Dermatol (2007) 1.13
Immunological suppression by human CD8+ T cells is receptor dependent and HLA-DQ restricted. Proc Natl Acad Sci U S A (1991) 1.12
Studies on human polymorphonuclear leukocyte enzymes. II. Comparative study of the physical properties of primary and specific granules. Biochim Biophys Acta (1973) 1.11
The surface membrane of Leishmania. I. The effects of lectins on different stages of Leishmania braziliensis. J Parasitol (1975) 1.09
Leprosy: confirmation in the armadillo. Science (1974) 1.05
Ethics of HIV trials. Lancet (1997) 1.04
IgM antibodies to native phenolic glycolipid-I in contacts of leprosy patients in Venezuela: epidemiological observations and a prospective study of the risk of leprosy. Int J Lepr Other Mycobact Dis (1991) 1.02
Ectopic skin lesions produced by Schistosoma mansoni. Am J Trop Med Hyg (1973) 1.00
Studies on plating efficiency and estimation of viability of suspensions of Paracoccidioides brasiliensis yeast cells. Mycopathologia (1980) 1.00
Immune response in healthy volunteers vaccinated with killed leishmanial promastigotes plus BCG. I: Skin-test reactivity, T-cell proliferation and interferon-gamma production. Vaccine (1994) 0.98
Results of a double blind study of the influence of thalidomide on the lepra reaction. Int J Lepr Other Mycobact Dis (1970) 0.98
Characterization and properties of alpha-D-mannosidase of human polymorphonuclear leucocytes. Clin Chim Acta (1973) 0.96
Vaccination in leprosy--observations and interpretations. Int J Lepr Other Mycobact Dis (1980) 0.96
Fabry's disease: normal alpha-galactosidase activity and urinary-sediment glycosphingolipid levels in two obligate heterozygotes. Br J Dermatol (1973) 0.93
Intermediate or chronic cutaneous leishmaniasis: leukocyte immunophenotypes and cytokine characterisation of the lesion. Exp Dermatol (2002) 0.93
A simple method for the differentiation of Mycobacterium leprae from other mycobacteria through routine staining technics. Int J Lepr Other Mycobact Dis (1973) 0.92
Delayed-type hypersensitivity and immunoglobulin E in American cutaneous leishmaniasis. Infect Immun (1982) 0.91
The development of a vaccination model using two microorganisms and its application in leprosy and leishmaniasis. Lepr Rev (1986) 0.91
Canine visceral leishmaniasis on Margarita Island (Nueva Esparta, Venezuela). Trans R Soc Trop Med Hyg (2000) 0.90
Immunotherapy with live BCG plus heat killed Leishmania induces a T helper 1-like response in American cutaneous leishmaniasis patients. Parasite Immunol (2000) 0.90
Differing antibody IgG isotypes in the polar forms of leprosy and cutaneous leishmaniasis characterized by antigen-specific T cell anergy. Clin Exp Immunol (1995) 0.90
Specificity of the 48-hour reaction to Mitsuda antigen. Use of a soluble antigen from human and armadillo lepromin. Bull World Health Organ (1975) 0.90
Sinefungin as treatment for American Leishmania in sensitive BALB/c and resistant C57BL/6 mice. Am J Trop Med Hyg (1990) 0.90
Serological and immunohistological studies on lepromatous leprosy. Int Arch Allergy Appl Immunol (1981) 0.88
The effect of fresh serum on the leptomonads of Leishmania. I. Preliminary report. Trans R Soc Trop Med Hyg (1968) 0.88
Defect of in vitro digestive ability of polymorphonuclear leukocytes in paracoccidioidomycosis. Infect Immun (1980) 0.88
Some considerations regarding the immunology of leprosy. Int J Lepr Other Mycobact Dis (1972) 0.88
Immunocytochemical characterization of immune cells in lesions of American cutaneous leishmaniasis using novel T cell markers. Acta Trop (1991) 0.87
Heterogeneity of acid phosphatase activity in human polymorphonuclear leukocytes. Clin Chim Acta (1973) 0.87
Specific IgG antibody responses may be used to monitor leprosy treatment efficacy and as recurrence prognostic markers. Eur J Clin Microbiol Infect Dis (2011) 0.87
Immune response in healthy volunteers vaccinated with BCG plus killed leishmanial promastigotes: antibody responses to mycobacterial and leishmanial antigens. Vaccine (1994) 0.87
Polymorphonuclear activation in leprosy. I. Spontaneous and endotoxin-stimulated reduction of nitroblue tetrazolium: effects of serum and plasma on endotoxin-induced activation. Clin Exp Immunol (1975) 0.85
Leishmania braziliensis causing visceral leishmaniasis in a patient with human immunodeficiency virus infection, identified with the aid of the polymerase chain reaction. Trans R Soc Trop Med Hyg (1994) 0.85
Immunological reactions in onchocerciasis. Trans R Soc Trop Med Hyg (1970) 0.85
Recent advances in the immunology of leprosy. Int J Dermatol (1976) 0.85
Spheroidal bodies and globi of human leprosy. Biochem Biophys Res Commun (1973) 0.84
Association of HLA specificity LB-E12 (MB1, DC1, MT1) with lepromatous leprosy in a Venezuelan population. Tissue Antigens (1984) 0.84
Study of the antibody response against Mycobacterium tuberculosis antigens in Warao Amerindian children in Venezuela. Mem Inst Oswaldo Cruz (2004) 0.84
A study of antibody response in leprosy. Int J Lepr Other Mycobact Dis (1969) 0.84
Cell-mediated immunity in localized cutaneous leishmaniasis patients before and after treatment with immunotherapy or chemotherapy. Parasite Immunol (1989) 0.83
Isolation of Leishmania infantum, zymodeme MON-1 from canine and human visceral leishmaniasis on Margarita Island, Venezuela. Mem Inst Oswaldo Cruz (2001) 0.82
Mononuclear cell subpopulations and infiltrating lymphocytes in erythema dyschromicum perstans and vitiligo. Histol Histopathol (1987) 0.82
The cutaneous lesion in American leishmaniasis: leukocyte subsets, cellular interaction and cytokine production. Biol Res (1993) 0.82
Immunotherapy and immunoprophylaxis of leprosy. Lepr Rev (1983) 0.82
Applying the indirect immunofluorescency test to the study of American cutaneous leishmaniasis. Dermatol Int (1969) 0.82
Histochemical identification of non-culturable mycobacteria (M. leprae and M. lepramurium). II. Dopa-oxidase. Histochemie (1973) 0.81
Studies on the effect of serum and proteins on in vitro-induced neutrophil activation. J Reticuloendothel Soc (1978) 0.81
Autoimmune diseases and thalidomide. II. Adjuvant disease, experimental allergic encephalomyelitis and experimental allergic neuritis of the rat. Int J Lepr Other Mycobact Dis (1975) 0.81
N.B.T. test in lepromatous leprosy. Lancet (1973) 0.80
Significance of neutrophil activation in reactional lepromatous leprosy: effects of thalidomide in vivo and in vitro. Activation in adjuvant disease. Int Arch Allergy Appl Immunol (1978) 0.80
Adhesion molecules in lesions of American cutaneous leishmaniasis. Exp Dermatol (1994) 0.80
Investigations related to the development of a leprosy vaccine. Int J Lepr Other Mycobact Dis (1983) 0.80
In vitro activation of neutrophils by suspensions of Mycobacterium leprae. Int J Lepr Other Mycobact Dis (1979) 0.80
Leukocytic enzyme differences between the clinical forms of malnutrition. Clin Chim Acta (1973) 0.80
New method for estimating digestion of Paracoccidioides brasiliensis by phagocytic cells in vitro. J Clin Microbiol (1979) 0.80
Therapy of leprosy. Bull World Health Organ (1970) 0.79
[Epidemiologic importance of age groups in colonies of the Simulium metallicum (Diptera: Simullidae) in Venezuela]. Bol Oficina Sanit Panam (1976) 0.79
Gamma interferon production induced by antigens in patients with leprosy and American cutaneous leishmaniasis. Am J Trop Med Hyg (1987) 0.79
Progressive, atrophying, chronic granulomatous dermohypodermitis. Autoimmune disease? Arch Dermatol (1973) 0.79
Serological patterns and specificity in American cutaneous leishmaniasis. Am J Trop Med Hyg (1988) 0.78
Density of epidermal Langerhans cells in psoriasis patients treated with an aromatic retinoid (RO 10-9359). An immunoperoxidase study using anti-T6 and anti-Ia monoclonal antibodies. Histol Histopathol (1986) 0.78
A follow-up study of multibacillary Hansen's disease patients treated with multidrug therapy (MDT) or MDT + immunotherapy (IMT). Int J Lepr Other Mycobact Dis (1997) 0.78
Discovery of a new onchocerciasis focus in Venezuela. Bull Pan Am Health Organ (1977) 0.78
Leukocyte subsets in the granulomatous response produced after inoculation with Mycobacterium leprae-BCG in lepromatous patients. Am J Trop Med Hyg (1988) 0.78
Studies on human polymorphonuclear leukocyte enzymes. 3. Differential activation of primary and specific granules by phospholipase C and deoxycholate. Biochim Biophys Acta (1974) 0.78
Albendazole in the treatment of onchocerciasis: double-blind clinical trial in Venezuela. Am J Trop Med Hyg (1992) 0.78
Tests with three antigens in leprosy-endemic and non-endemic areas. Bull World Health Organ (1975) 0.78
Leishmania species: comparative ultrastructure of experimental nodules and diffuse human cutaneous lesions in American leishmaniases. Exp Parasitol (1983) 0.78
Germicidal activity of a polyenzymic system on pathogenic protozoa in vitro. Arch Int Physiol Biochim (1975) 0.78
Effectiveness of dapsone in Behcet's disease. Br J Dermatol (1984) 0.77